-
Je něco špatně v tomto záznamu ?
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
A. Spyridonidis, M. Labopin, E. Brissot, I. Moiseev, J. Cornelissen, G. Choi, F. Ciceri, J. Vydra, P. Reményi, M. Rovira, E. Meijer, H. Labussière-Wallet, D. Blaise, G. van Gorkom, N. Kröger, Y. Koc, S. Giebel, A. Bazarbachi, B. Savani, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 1997-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * farmakoterapie MeSH
- antilymfocytární sérum terapeutické užití MeSH
- cyklofosfamid terapeutické užití MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli * MeSH
- nepříbuzný dárce MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- transplantace periferních kmenových buněk * metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.
Bone Marrow Transplant Unit Medicana International Hospital Istanbul Turkey
Dél pesti Centrumkórház Budapest Hungary
Department of Hematology Hospital Saint Antoine Paris France
EBMT Statistical Unit Sorbonne Université Hospital Saint Antoine Paris France
Erasmus MC Cancer Institute University Medical Center Rotterdam Netherlands
Gorbacheva Research Institute Pavlov Univ St Petersburg Russian Federation
Hematology Division Chaim Sheba Medical Center Tel Hashomer Israel
Hôpital Lyon Sud Hospices Civils de Lyon Pierre Bénite France
Hospital Clinic Institute of Hematology and Oncology Barcelona Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Poland
Ospedale San Raffaele s r l Haematology and BMT Milano Italy
University Hospital Eppendorf Bone Marrow Transplant Centre Hamburg Germany
University Hospital Maastricht Maastricht Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032441
- 003
- CZ-PrNML
- 005
- 20240528145712.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-022-01816-1 $2 doi
- 035 __
- $a (PubMed)36071114
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spyridonidis, Alexandros $u Bone Marrow Transplantation Unit and Institute of Cellular Therapy, University of Patras, Patras, Greece. spyridonidis@upatras.gr $1 https://orcid.org/0000000330972532
- 245 10
- $a Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT / $c A. Spyridonidis, M. Labopin, E. Brissot, I. Moiseev, J. Cornelissen, G. Choi, F. Ciceri, J. Vydra, P. Reményi, M. Rovira, E. Meijer, H. Labussière-Wallet, D. Blaise, G. van Gorkom, N. Kröger, Y. Koc, S. Giebel, A. Bazarbachi, B. Savani, A. Nagler, M. Mohty
- 520 9_
- $a In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a antilymfocytární sérum $x terapeutické užití $7 D000961
- 650 12
- $a transplantace periferních kmenových buněk $x metody $7 D036102
- 650 _2
- $a nepříbuzný dárce $7 D061349
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $7 D015470
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Labopin, Myriam $u EBMT Statistical Unit, Sorbonne Université, Hospital Saint-Antoine, Paris, France $1 https://orcid.org/0000000345144748
- 700 1_
- $a Brissot, Eolia $u Department of Hematology, Hospital Saint Antoine, Paris, France $1 https://orcid.org/000000034471418X
- 700 1_
- $a Moiseev, Ivan $u Gorbacheva Research Institute, Pavlov Univ., St Petersburg, Russian Federation $1 https://orcid.org/0000000243320114
- 700 1_
- $a Cornelissen, Jan $u Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands
- 700 1_
- $a Choi, Goda $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Ciceri, Fabio $u Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
- 700 1_
- $a Reményi, Péter $u Dél-pesti Centrumkórház, Budapest, Hungary
- 700 1_
- $a Rovira, Montserrat $u Hospital Clinic, Institute of Hematology & Oncology, Barcelona, Spain
- 700 1_
- $a Meijer, Ellen $u VU University Medical Center, Amsterdam, Netherlands
- 700 1_
- $a Labussière-Wallet, Hélène $u Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Marseille, France $1 https://orcid.org/0000000256849447
- 700 1_
- $a van Gorkom, Gwendolyn $u University Hospital Maastricht, Maastricht, Netherlands
- 700 1_
- $a Kröger, Nicolaus $u University Hospital Eppendorf, Bone Marrow Transplant Centre, Hamburg, Germany $1 https://orcid.org/0000000151039966
- 700 1_
- $a Koc, Yener $u Bone Marrow Transplant Unit, Medicana International Hospital, Istanbul, Turkey
- 700 1_
- $a Giebel, Sebastian $u Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland $1 https://orcid.org/0000000248274401
- 700 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut-Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000271714997
- 700 1_
- $a Savani, Bipin N. $u Vanderbilt University Medical Center, Nashville, TN, USA $1 https://orcid.org/0000000233049965 $7 xx0317726
- 700 1_
- $a Nagler, Arnon $u Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel $1 https://orcid.org/0000000207631265
- 700 1_
- $a Mohty, Mohamad $u Department of Hematology, Hospital Saint Antoine, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 12 (2022), s. 1774-1780
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36071114 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20240528145709 $b ABA008
- 999 __
- $a ok $b bmc $g 1891289 $s 1183776
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 57 $c 12 $d 1774-1780 $e 20220907 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20230120
